(INNV) MC $5 M /Float 3.3 M /2x Big Product Launchs imminent

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
(INNV) MC $5 M /Float 3.3 M /2x Big Product Launchs imminent

An SI Board Since September 2013

Posts	SubjectMarks	Bans
1	1	0

Emcee: BioHero	Type: Moderated

Introduction Compact

Thats a Stock called a REAL LIFETIME OPPORTUNITY . Please Do your own DD and you will know why .GL

This Unknown Goldmine has One Product on the Market since May 2013 and another Two Big Products will be launched in 4Q 2013 . More Partner Deals coming before Year End which will bring more Cash to the Company . The Most of the Products targeting a Multi-Billion-Dollar Market . CEO says main goal for 2014 is Nasdaq-Listing means he expect that this Low Float Rocket to move over $3 because this is a requirement for Nasdaq-Listing .

At $10 this Stock would have a Market Cpa of Only $170 M and thats achievable with their Products which have HUGE Market Potential .

Innovus Pharmaceutical (INNV)

Market Cap: $5.3 Million
Cash : $1.2 M
Price: $0.33

Shares Out : 17.7 Million
Float : 3.3 Million

Ceo Buying a lot of Shares

finance.yahoo.com

Presentation August 2013 :

innovuspharma.com

Fact Sheet August 2013 :

innovuspharma.com

CEOLIVE Interview with Dr. Bassam Damaj, CEO of Innovus Pharmaceuticals
youtube.com

Upcoming Milestone 2013 :

•First commercial ex-US sales of CIRCUMserum occurred in May 2013

•Secure commercial partnerships/distributors in the MENA countries for CIRCUMserum andEjectDelay

•Launch of EjectDelay for Premature Ejaculation and Apeaz for Arthritis Pain Relief in the US in Q4 2013

The estimated U.S. market size for treatment of osteoarthritis is $5+ billion annually

Monster Pipeline :

Product Route Stage Disease Territory Exp.Launch Date

CIRCUMserum™ Topical OTC Reduced Penile Sensitivity Ex-US Marketed

EjectDelay™ Topical OTC Compliant Premature Ejaculation Worldwide Q4 2013

Apeaz™ Topical OTC Compliant Arthritis Pain Worldwide Q4 2013

Acne Care Topical OTC Registration Acne Treatment Worldwide Q1 2014

Cough/Cold Lozenges Oral OTC Cough & Cold Reduction Worldwide Q2 1014

Xyralid™ Topical OTC Registration Anesthetic Worldwide Q1 2014

Go to reply# or date (mm/dd/yy):